Long-term maintenance with P2Y12 inhibitor monotherapy after discontinuing dual antiplatelet therapy (DAPT) in patients who’ve undergone PCI seems to reduce MACCE compared with aspirin monotherapy ...

Early aspirin discontinuation and transition to a P2Y12 inhibitor monotherapy may lower bleeding risk in those at low ...

For long-term secondary prevention of MI, the use of P2Y12 monotherapy has a borderline advantage over aspirin alone and does not affect bleeding, according to a meta-analysis of nine randomized ...

BARCELONA -- Patients with documented coronary artery disease (CAD) saw cardiovascular benefits with P2Y12-inhibitor monotherapy when compared with aspirin alone, according to the PANTHER ...

Please provide your email address to receive an email when new articles are posted on . Valgimigli is deputy chief of interventional cardiology at Cardiocentro Ticino Institute, Lugano, Switzerland.

Please provide your email address to receive an email when new articles are posted on . In a cohort of noncritically ill patients with COVID-19, the addition of a P2Y12 inhibitor to anticoagulation ...

Background: The initial results for CURRENT-OASIS 7 were presented at the European Society of Cardiology Congress 2009 in Barcelona. To date, final analyses of the study have not been published in a ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

On Thursday, May 28, Hunterdon Medical Center's Mobile Intensive Care Unit became the first in the nation to add a P2Y12 inhibitor (a classification of medications for anti-platelet inhibitors) , an ...

Giving a P2Y12 inhibitor anti-clotting drug to patients with coronary artery disease is associated with lower rates of cardiovascular death, heart attack and stroke compared with traditional aspirin, ...

What The Study Did: In this randomized clinical trial with 562 noncritically ill patients hospitalized for COVID-19, the use of a P2Y12 inhibitor combined with a therapeutic dose of heparin didn’t ...

A P2Y12 inhibitor, such as clopidogrel or ticagrelor, might be a better choice than aspirin for antiplatelet monotherapy in patients with coronary artery disease, results of a new meta-analysis ...